Search Results for: covid-19
Articles
Monoclonal vs Polyclonal Antibody Production – Explained Step by Step
Antibody-based therapeutics have reshaped modern medicine. With demand soaring, choosing the appropriate production path can save months and millions.
According to Grand View Research, the global therapeutic antibody market will surpass US $2.21 billion by 2030.
Based on our expertise in monoclonal antibody production, let’s take a look at how each antibody type is produced, contrasts their timelines, costs, and use-cases, and ends with clear next steps to keep your project moving.
FDA Approves the First Ever mRNA Flu Vaccine From Moderna
The FDA approved Moderna’s mRNA vaccine, mFlusiva, to prevent seasonal influenza in adults 50 years of age and older. This...Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
CAMBRIDGE, Mass., -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of...2026 Nasal & Inhalation Drug Development & Delivery eBook: Drug Repurposing Creates New Market Opportunities
In this exclusive seventh annual nasal and inhalation eBook, Drug Development & Delivery highlights how these routes of administration are bringing new life to orphaned drugs and open new opportunities for treatment beyond pulmonary and respiratory diseases. We also explore the challenges of nose-to-brain delivery, next-generation propellants, overcoming the limitations of dry powder inhalers, and successful formulation strategies.
SPECIAL REPORT - Advancements in Respiratory Drug Delivery
Advances in inhaled drug delivery are improving how therapies reach the lungs, with innovations in formulations, devices, biologics, and digital tools helping expand treatment options for respiratory diseases.
NeoVac Announces Positive Results Demonstrating Superior Safety Profile of Next-Generation mRNA-LNP Vaccine Platform
NeoVac recently announced positive results from first-in-human Phase I/II clinical study of NeomiVac, its investigational mRNA-LNP COVID-19 vaccine candidate. The clinical...CELL & GENE THERAPY - What the Industry Can Learn From Baby KJ About Optimizing CRISPR Development
Venkata Indurthi, PhD, believes the success of Baby KJ provides a model that could be replicated many times over to treat people with ultra-rare genetic diseases.
MRNA THERAPEUTICS - Strategies for Enhanced Stability, Targeted Delivery & Safe Translation
Carsten Rudolph, PhD, explores many challenges and the solutions offered by novel technology platforms, providing insight into the evolving landscape of mRNA drug development and its potential as a future transformative modality.
3D PRINTING - The Future of 3D Printing in Pharma: Aprecia’s Vision for Transformative Medicine
Kyle Smith, MBA, explains how his company, a pioneer in pharmaceutical 3D printing, has a vision for distributed, patient-centric manufacturing that could re-shape the future of medicine.
Traws Pharma Doses First Patient With Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Traws Pharma, Inc. recently announced the dosing of the first subject in a Phase 2 study to evaluate ratutrelvir, a ritonavir-free...
